ADC Therapeutics S.A. (ADCT): Price and Financial Metrics
ADCT Price/Volume Stats
| Current price | $4.37 | 52-week high | $6.04 |
| Prev. close | $4.37 | 52-week low | $0.36 |
| Day low | $4.30 | Volume | 119,359 |
| Day high | $4.60 | Avg. volume | 770,753 |
| 50-day MA | $4.55 | Dividend yield | N/A |
| 200-day MA | $2.12 | Market Cap | 360.66M |
ADCT Stock Price Chart Interactive Chart >
ADC Therapeutics S.A. (ADCT) Company Bio
ADC Therapeutics SA is a clinical-stage biotechnology company, which develops antibody drug conjugates. Its products include Lonca, Cami and ADCT-602. Its drugs are used in treating various advanced solid tumors. The company was founded on June 6, 2011 and is headquartered in Epalinges, Switzerland.
Latest ADCT News From Around the Web
Below are the latest news stories about ADC THERAPEUTICS SA that investors may wish to consider to help them evaluate ADCT as an investment opportunity.
ADC Therapeutics SA (NYSE:ADCT) institutional owners may be pleased with recent gains after 46% loss over the past yearKey Insights Institutions' substantial holdings in ADC Therapeutics implies that they have significant influence over... |
ADC Therapeutics Announces Initial Results from Investigator-Initiated Phase 2 Clinical Trial Evaluating ZYNLONTA® in Combination with Rituximab in Patients with Relapsed/Refractory Follicular Lymphoma (FL)Combination demonstrated clinically meaningful benefit in r/r FL patients with 96% overall response rate and 85% complete response rate LAUSANNE, Switzerland, Dec. 12, 2023 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT) today announced initial results from an investigator-initiated Phase 2 clinical trial evaluating ZYNLONTA® (loncastuximab tesirine-lpyl) in combination with rituximab demonstrated a high response rate in patients with relapsed or refractory (r/r) follicular lymphoma (FL). T |
Sobi to present new data at ASH 2023 Annual MeetingSobi® will present new data at the 65th Annual Meeting of the American Society of Hematology (ASH) in San Diego from the 9th to the 12th of December 2023. During the meeting several analyses will be presented in patients with haemophilia A, paroxysmal nocturnal hemoglobinuria (PNH), immune thrombocytopenia (ITP), relapsed or refractory diffuse large b-cell lymphoma, myelofibrosis, and haemophagocytic lymphohistiocytosis. |
Myricx Bio Appoints Dr Chris Martin, Biotech Entrepreneur and ADC Pioneer, as Chairman of its Board of DirectorsDr Chris Martin Dr Chris Martin, Chairman of Myricx LONDON, Nov. 15, 2023 (GLOBE NEWSWIRE) -- Myricx Bio (‘Myricx’), a UK biotech company focused on the discovery and development of a completely novel class of antibody-drug conjugate (ADC) payloads based on N-Myristoyltransferase inhibition (NMTi), today announces the appointment of Dr Chris Martin as independent Chairman to its Board of Directors. Dr Martin is a renowned biotech company founder, director and entrepreneur, and a pioneer and lead |
ADC Therapeutics SA (NYSE:ADCT) Q3 2023 Earnings Call TranscriptADC Therapeutics SA (NYSE:ADCT) Q3 2023 Earnings Call Transcript November 7, 2023 ADC Therapeutics SA beats earnings expectations. Reported EPS is $-0.58, expectations were $-0.61. Operator: Welcome to the ADC Therapeutics Third Quarter 2023 Financial Results Conference Call. My name is Cathy and I will be your operator for today’s call. At this time, all […] |
ADCT Price Returns
| 1-mo | 15.61% |
| 3-mo | 134.95% |
| 6-mo | 463.14% |
| 1-year | 82.08% |
| 3-year | -81.24% |
| 5-year | N/A |
| YTD | 163.25% |
| 2023 | -56.77% |
| 2022 | -80.99% |
| 2021 | -36.89% |
| 2020 | N/A |
| 2019 | N/A |
Loading social stream, please wait...